Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.80 |
| ▸ | CNR1 | P21554 | 4/20 | 0.80 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258447 | 1.00 | CNR2 (0.80) | CNR2CNR1EPHX1PPARGPPARD | |
| SCHEMBL1946504 | 1.00 | CNR2 (0.80) | CNR2CNR1EPHX1PPARGPPARD | |
| SCHEMBL258448 | 1.00 | CNR2 (0.80) | CNR2CNR1EPHX1PPARGPPARD | |
| SCHEMBL20883258 | 1.00 | CNR2 (0.80) | CNR2CNR1EPHX1PPARGPPARD | |
| SCHEMBL20883283 | 1.00 | CNR2 (0.80) | CNR2CNR1EPHX1PPARGPPARD | |
| SCHEMBL5553152 | 1.00 | CNR2 (0.80) | CNR2CNR1EPHX1PPARGPPARD | |
| SCHEMBL1030756 | 1.00 | CNR2 (0.80) | CNR2CNR1EPHX1PPARGPPARD | |
| SCHEMBL4205215 | 0.95 | CNR2 (0.73) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL29406024 | 0.90 | CNR2 (0.66) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL2262688 | 0.89 | CNR2 (1.00) | CNR2CNR1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9468225-B2 | Oral compositions | SYMRISE AG (DE) | 2016-10-18 | — | — | US | disclosed |
| US-20140234412-A1 | ORAL COMPOSITIONS | SYMRISE AG (DE) | 2014-08-21 | — | — | US | disclosed |
| US-20070202188-A1 | Use of alkene carboxlic acid n alkylamides as flavouring agents | SYMRISE GMBH & CO. KG (DE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234412-A1 | ORAL COMPOSITIONS | FABP4, GPR119, FABP2 | CNR2 89/4885CNR1 262/4885EPHX1 2656/4885 |
| US-20070202188-A1 | Use of alkene carboxlic acid n alkylamides as flavouring agents | TAS2R41, TAS2R1, TAS2R14 | CNR2 43/4885CNR1 49/4885EPHX1 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.